Pharmacosmos to invest in Chinese organization following reimbursement win
The Danish company is the first in China to receive reimbursement approval for a high-dose iron deficiency drug, says Pharmacosmos CEO Tobias Christensen – but the competition is hot on their heels.
by ulrich quistgaard, translated by daniel pedersen
It is clearly an advantage to be the first to have a high-dose product to treat iron deficiency and iron deficiency anemia in the world’s second-biggest market for the disorder, says Pharmacosmos CEO Tobias S. Christensen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos wins Chinese reimbursement deal
For subscribers
Pharmacosmos tight-lipped on competitor's Chinese market nod
For subscribers
